Education
About Us
Working with TipRanks
Follow Us
United Therapeutics (UTHR)
NASDAQ:UTHR
UTHR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$233.28 - $417.82
Previous CloseN/A
Volume58.00K
Average Volume (3M)488.90K
Market Cap
$13.15B
Enterprise Value$14.22B
Total Cash (Recent Filing)$189.96M
Total Debt (Recent Filing)$254.69M
Price to Earnings (P/E)11.9
Beta0.59
Next Earnings
Apr 30, 2025EPS Estimate
6.66Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)24.60
Shares Outstanding44,912,178
10 Day Avg. Volume493,714
30 Day Avg. Volume488,897
Financial Highlights & Ratios
PEG Ratio0.46
Price to Book (P/B)N/A
Price to Sales (P/S)4.89
Price to Cash Flow (P/CF)10.30
P/FCF Ratio13.80
Enterprise Value/Market Cap1.08
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit5.54
Enterprise Value/Ebitda8.84
Forecast
1Y Price Target
$383.18Price Target Upside30.57% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
---
United Therapeutics News
See All UTHR News
---
Bulls Say, Bears Say
Bulls Say
Growth PotentialThe company expects double-digit growth, indicating strong future performance potential.
Market PositionNo substantial near-term competition is expected for the commercial franchise, which bodes well for the company's market position.
ValuationThe recent sell-off has pushed the stock near floor valuation levels, making it an attractive buy from a risk/reward perspective.
Bears Say
CompetitionUnited Therapeutics faces competitive headwinds to its core cardiopulmonary franchises, with threats from multiple competitors.
Market PressureThe stock has been under pressure due to anticipated Yutrepia approval and potential Winrevair competition.
Revenue DeclineThe 4Q24 results revealed that Tyvaso franchise revenue declined slightly from ~$434M in 3Q24 to ~$416M in 4Q24, reflecting a ~4% Q/Q decline.
---
Ownership Overview
7.07% Insiders
25.76% Mutual Funds
0.89% Other Institutional Investors
37.43% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
UTHR FAQ
What was United Therapeutics’s price range in the past 12 months?
United Therapeutics lowest stock price was $233.28 and its highest was $417.81 in the past 12 months.
What is United Therapeutics’s market cap?
United Therapeutics’s market cap is $13.15B.
When is United Therapeutics’s upcoming earnings report date?
United Therapeutics’s upcoming earnings report date is Apr 30, 2025 which is in 6 days.
How were United Therapeutics’s earnings last quarter?
United Therapeutics released its earnings results on Feb 26, 2025. The company reported $6.19 earnings per share for the quarter, missing the consensus estimate of $6.4 by -$0.21.
Is United Therapeutics overvalued?
According to Wall Street analysts United Therapeutics’s price is currently Undervalued.
Does United Therapeutics pay dividends?
United Therapeutics does not currently pay dividends.
What is United Therapeutics’s EPS estimate?
United Therapeutics’s EPS estimate is 6.66.
How many shares outstanding does United Therapeutics have?
United Therapeutics has 44,912,178 shares outstanding.
What happened to United Therapeutics’s price movement after its last earnings report?
United Therapeutics reported an EPS of $6.19 in its last earnings report, missing expectations of $6.4. Following the earnings report the stock price went down -10.8%.
Which hedge fund is a major shareholder of United Therapeutics?
Currently, no hedge funds are holding shares in UTHR
---
United Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$383.18 (30.57% Upside)
$383.18 (30.57% Upside)
Blogger Sentiment
Bullish
UTHR Sentiment 90%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 39.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $6.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 6.2%
Last 30 Days ▼ 6.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
25.10%
12-Months-Change
Fundamentals
Return on Equity
19.23%
Trailing 12-Months
Asset Growth
3.18%
Trailing 12-Months
Company Description
United Therapeutics
United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions. Headquartered in Silver Spring, Maryland, the company is primarily engaged in the pharmaceutical and biotechnology sectors. Its core products include treatments for pulmonary arterial hypertension (PAH), such as Remodulin, Tyvaso, Orenitram, and Unituxin for pediatric neuroblastoma.
---
UTHR Company Deck
---
UTHR Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted United Therapeutics' record-breaking revenue and strong growth across major product lines. The company is progressing well with its innovative clinical trials and strategic capital allocation, despite a slight sequential decline in net revenue for Q4 due to contracting adjustments. The sentiment is largely positive, focusing on future growth and advancements.Read More>---
UTHR Revenue Breakdown
53.01% Tyvaso
21.26% Remodulin
15.44% Orenitram
8.55% Unituxin
1.75% Other
---
UTHR Stock 12 Month Forecast
Average Price Target
$383.18
▲(30.57% Upside)
Technical Analysis
Best Analysts Covering UTHR
1 Year
1 Year Success Rate
11/17 ratings generated profit
1 Year Average Return
+15.22%
reiterated a buy rating 3 days ago
Copying Jessica Fye's trades and holding each position for 1 Year would result in 64.71% of your transactions generating a profit, with an average return of +15.22% per trade.
---